Biohaven Pharmaceutical Holding Company Ltd.
BHVN
BHVN was delisted on the 3rd of October, 2022.
170 hedge funds and large institutions have $1.98B invested in Biohaven Pharmaceutical Holding Company Ltd. in 2019 Q1 according to their latest regulatory filings, with 51 funds opening new positions, 60 increasing their positions, 34 reducing their positions, and 11 closing their positions.
364% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 11
130% more call options, than puts
Call options by funds: $57.2M | Put options by funds: $24.9M
76% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 34
39% more capital invested
Capital invested by funds: $1.42B → $1.98B (+$558M)
30% more funds holding
Funds holding: 131 → 170 (+39)
9% more funds holding in top 10
Funds holding in top 10: 11 → 12 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
+$36.6M |
| 2 |
BlackRock
New York
|
+$20.1M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$19.4M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$15.6M |
| 5 |
State Street
Boston,
Massachusetts
|
+$14.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$81.7M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$56.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.6M |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
-$16.3M |
| 5 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$14.6M |
BHVN Hedge Fund Activity: Q1 2019 in Review
170 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q1 2019, worth a combined $1.98B — up 39% from $1.42B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new BHVN positions and 11 closed out — a net gain of 40 holders — while 60 added to existing stakes and 34 trimmed.
The largest buyer was Oracle Investment Management, adding an estimated $36.6M. The largest seller was Janus Henderson Group, cutting an estimated $81.7M.
- 170 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q1 2019, up from 131 in Q4 2018.
- Funds reported $1.98B of Biohaven Pharmaceutical Holding Company Ltd. stock for Q1 2019, up 39% quarter-over-quarter.
- 51 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q1 2019 and 11 closed out, a net change of +40 holders.
- The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q1 2019 was Oracle Investment Management, an estimated $36.6M added.
- The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q1 2019 was Janus Henderson Group, an estimated $81.7M sold.
Based on aggregated 13F filings for Q1 2019.